Your Article Summary
See Latest ArticlesRivaroxaban: An Oral Direct Factor Xa Inhibitor for the Prevention of Thromboembolism
Cardiology In Review, 06/19/09
Chen T et al. - Rivaroxaban is a novel oral direct factor Xa inhibitor. Rivaroxaban has been shown to have tolerable adverse effects and a low potential for drug-drug or drug-food interactions. It has the major advantages of once daily oral dosing and no required laboratory monitoring, giving it the potential to replace current antithrombotics in the market today.
Related Articles
A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
PharmacoEconomics, 10/12/09
Relevance Score: 89%
The new oral anticoagulants
Blood, 11/13/09
Relevance Score: 80%
Today in CV/Thromboembolic...keeping you current
Receive free subspecialty "5-minute updates" via email
The Prevalence of Clinically Relevant Incidental Findings on Chest Computed Tomographic Angiograms Ordered to Diagnose Pulmonary Embolism
Archives of Internal Medicine, 11/25/09
Transthoracic Sonography in Comparison to Multislice Computed Tomography in Detection of Peripheral Pulmonary Embolism
Lung, 11/25/09
Short term effect of recombinant tissue plasminogen activator in patients with hemodynamically stable acute pulmonary embolism: Results of a meta-analysis involving 464 patients
Thrombosis Research, 11/25/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Chronic Obstructive Pulmonary Disease: Role of Bacteria and Updated Guide to Antibacterial Selection in the Older Patient
Drugs & Aging, 11/25/09
Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages
European Respiratory Journal , 11/25/09
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
Journal of Allergy and Clinical Immunology, 11/25/09